UCB to Buy Epilepsy Drugmaker Zogenix for Up to $1.9B

• • Facebook
  • Twitter
  • LinkedIn

  • Digg
  • Google

Fried Frank acted as counsel to BofA Securities and SVB Leerink as financial advisors to Zogenix, Inc., a US producer of drugs to treat seizures and rare diseases, in its US$1.9 billion acquisition by Belgian pharmaceutical company UCB SA (UCB). The transaction will expand UCB's portfolio of drug and treatment targets to include epilepsy.

Corporate partners Philip Richter and Roy Tannenbaum and corporate law clerk Trent Pacer advised BofA Securities and corporate partner Warren S. de Wied advised SVB Leerink.